Pulmonary Vascular Disease |

Success of Educational Interventions on Pulmonary Arterial Hypertension Management FREE TO VIEW

Nimish Mehta, PhD; Tara Herrmann, PhD; Chad Williamson, MS; Steven Nathan, MD
Author and Funding Information

Medscape, LLC, New York, NY

Chest. 2013;144(4_MeetingAbstracts):859A. doi:10.1378/chest.1704650
Text Size: A A A
Published online


SESSION TITLE: DVT/PE/Pulmonary Hypertension Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: Pulmonary arterial hypertension (PAH) is under-recognized and inadequately treated. A study was conducted to determine if on-line educational interventions could improve competence and performance of pulmonologists and cardiologists with respect to PAH management.

METHODS: A cohort of US-practicing pulmonologists and cardiologists was identified prior to the launch of a series of four educational interventions designed to address gaps in care of patients with PAH. The outcomes survey method, previously validated to measure performance, included knowledge- and case-based, multiple-choice questions based on current evidence-based recommendations for the assessment and management of patients with PAH. Responses from the clinical cases and questions aligned to individual interventions were collected and compared with baseline data in order to assess the impact of education on the practice patterns of participants.

RESULTS: In total, 427 pulmonologists and cardiologists participated in this assessment. Compared with the baseline assessment, significant improvements were found as a result of participation in the educational interventions, specifically: - Post-education more cardiologists selected right heart catheterization to diagnose PAH (73% post education vs 53% baseline, P=.01) - 13% more pulmonologists (P=.04) vs baseline correctly identified 25 mm Hg as the cut-off mPAP value to diagnose PAH - 19% more pulmonologists (68% before and 87% after; P=.006) and 23% more cardiologists (65% before and 88% after; P=.03) recognized the action of PDE-5 inhibitors in relation to PAH pathogenesis - Pulmonologists (P=.004) and cardiologists (P=.04) were more likely to recognize the the goals of combination therapy - More cardiologists would consider combination therapy for PAH in the appropriate clinical circumstance after participation (76% before and 98% after; P=.002)

CONCLUSIONS: This study demonstrated the success of targeted educational interventions on improving the practice patterns of pulmonologists and cardiologists in the assessment and management of patients with PAH.

CLINICAL IMPLICATIONS: Statistically significant improvements in several domains of PAH management is expected to result in improvements in patient care and outcomes.

DISCLOSURE: Steven Nathan: Consultant fee, speaker bureau, advisory committee, etc.: Actelion, Gilead and United Therapeutics, Grant monies (from industry related sources): Actelion, Gilead, United Therapeutics, and Aires Pharmaceutical The following authors have nothing to disclose: Nimish Mehta, Tara Herrmann, Chad Williamson

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543